264 related articles for article (PubMed ID: 32532212)
1. The prevalence of cryptococcal antigen (CrAg) and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell counts < 200 cells/μL: evidence based on a meta-analysis.
Li Y; Huang X; Chen H; Qin Y; Hou J; Li A; Wu H; Yan X; Chen Y
BMC Infect Dis; 2020 Jun; 20(1):410. PubMed ID: 32532212
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a national cryptococcal antigen screening program for HIV-infected patients in Uganda: A cost-effectiveness modeling analysis.
Rajasingham R; Meya DB; Greene GS; Jordan A; Nakawuka M; Chiller TM; Boulware DR; Larson BA
PLoS One; 2019; 14(1):e0210105. PubMed ID: 30629619
[TBL] [Abstract][Full Text] [Related]
3. Cryptococcal antigen prevalence in HIV-infected Tanzanians: a cross-sectional study and evaluation of a point-of-care lateral flow assay.
Rugemalila J; Maro VP; Kapanda G; Ndaro AJ; Jarvis JN
Trop Med Int Health; 2013 Sep; 18(9):1075-1079. PubMed ID: 23937699
[TBL] [Abstract][Full Text] [Related]
4. Estimated Prevalence of Cryptococcus Antigenemia (CrAg) among HIV-Infected Adults with Advanced Immunosuppression in Namibia Justifies Routine Screening and Preemptive Treatment.
Sawadogo S; Makumbi B; Purfield A; Ndjavera C; Mutandi G; Maher A; Kaindjee-Tjituka F; Kaplan JE; Park BJ; Lowrance DW
PLoS One; 2016; 11(10):e0161830. PubMed ID: 27760140
[TBL] [Abstract][Full Text] [Related]
5. Prospective cohort of AIDS patients screened for cryptococcal antigenaemia, pre-emptively treated and followed in Brazil.
Borges MASB; de Araújo Filho JA; Oliveira BJS; Moreira IS; de Paula VV; de Bastos AL; Soares RBA; Turchi MD
PLoS One; 2019; 14(7):e0219928. PubMed ID: 31344140
[TBL] [Abstract][Full Text] [Related]
6. Cryptococcal antigenemia is associated with meningitis or death in HIV-infected adults with CD4 100-200 cells/mm
Wykowski J; Galagan SR; Govere S; Wallis CL; Moosa MY; Celum C; Drain PK
BMC Infect Dis; 2020 Jan; 20(1):61. PubMed ID: 31959112
[TBL] [Abstract][Full Text] [Related]
7. Asymptomatic cryptococcal antigen prevalence detected by lateral flow assay in hospitalised HIV-infected patients in São Paulo, Brazil.
Vidal JE; Toniolo C; Paulino A; Colombo A; Dos Anjos Martins M; da Silva Meira C; Pereira-Chioccola VL; Figueiredo-Mello C; Barros T; Duarte J; Fonseca F; Alves Cunha M; Mendes C; Ribero T; Dos Santos Lazera M; Rajasingham R; Boulware DR
Trop Med Int Health; 2016 Dec; 21(12):1539-1544. PubMed ID: 27699970
[TBL] [Abstract][Full Text] [Related]
8. Cryptococcal infection in HIV-infected patients with CD4
Pérez-Jacoiste Asín MA; Bisbal O; Iribarren JA; Pérez-Rivilla A; Mican R; Dronda F; González-Domenech CM; Vinuesa-García D; Macías J; Lumbreras C; Moreno S; Rubio R;
Clin Microbiol Infect; 2021 Aug; 27(8):1171.e1-1171.e7. PubMed ID: 33069858
[TBL] [Abstract][Full Text] [Related]
9. CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis.
Ford N; Shubber Z; Jarvis JN; Chiller T; Greene G; Migone C; Vitoria M; Doherty M; Meintjes G
Clin Infect Dis; 2018 Mar; 66(suppl_2):S152-S159. PubMed ID: 29514236
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of screening and treatment of cryptococcal antigenaemia among HIV-infected persons in Soweto, South Africa.
Govender NP; Roy M; Mendes JF; Zulu TG; Chiller TM; Karstaedt AS
HIV Med; 2015 Sep; 16(8):468-76. PubMed ID: 25689352
[TBL] [Abstract][Full Text] [Related]
11. Prevalence, correlates, and outcomes of cryptococcal antigen positivity among patients with AIDS, United States, 1986-2012.
McKenney J; Bauman S; Neary B; Detels R; French A; Margolick J; Doherty B; Klausner JD
Clin Infect Dis; 2015 Mar; 60(6):959-65. PubMed ID: 25422390
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and mortality of cryptococcal disease in adults with advanced HIV in an urban tertiary hospital in Sierra Leone: a prospective study.
Lakoh S; Rickman H; Sesay M; Kenneh S; Burke R; Baldeh M; Jiba DF; Tejan YS; Boyle S; Koroma C; Deen GF; Beynon F
BMC Infect Dis; 2020 Feb; 20(1):141. PubMed ID: 32059703
[TBL] [Abstract][Full Text] [Related]
13. Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 <100 Cells/µL: A Stepped-Wedge, Cluster-Randomized Trial.
Meya DB; Kiragga AN; Nalintya E; Morawski BM; Rajasingham R; Park BJ; Mubiru A; Kaplan JE; Manabe YC; Boulware DR
J Acquir Immune Defic Syndr; 2019 Feb; 80(2):182-189. PubMed ID: 30399034
[TBL] [Abstract][Full Text] [Related]
14. Establishing a cost-per-result of laboratory-based, reflex Cryptococcal antigenaemia screening (CrAg) in HIV+ patients with CD4 counts less than 100 cells/μl using a Lateral Flow Assay (LFA) at a typical busy CD4 laboratory in South Africa.
Cassim N; Schnippel K; Coetzee LM; Glencross DK
PLoS One; 2017; 12(2):e0171675. PubMed ID: 28166254
[TBL] [Abstract][Full Text] [Related]
15. Neurocognitive function in HIV-infected persons with asymptomatic cryptococcal antigenemia: a comparison of three prospective cohorts.
Montgomery MP; Nakasujja N; Morawski BM; Rajasingham R; Rhein J; Nalintya E; Williams DA; Huppler Hullsiek K; Kiragga A; Rolfes MA; Donahue Carlson R; Bahr NC; Birkenkamp KE; Manabe YC; Bohjanen PR; Kaplan JE; Kambugu A; Meya DB; Boulware DR;
BMC Neurol; 2017 Jun; 17(1):110. PubMed ID: 28606065
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of cryptococcal antigenemia and cost-effectiveness of a cryptococcal antigen screening program--Vietnam.
Smith RM; Nguyen TA; Ha HT; Thang PH; Thuy C; Lien TX; Bui HT; Le TH; Struminger B; McConnell MS; Fanfair RN; Park BJ; Harris JR
PLoS One; 2013; 8(4):e62213. PubMed ID: 23626792
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.
Meya DB; Manabe YC; Castelnuovo B; Cook BA; Elbireer AM; Kambugu A; Kamya MR; Bohjanen PR; Boulware DR
Clin Infect Dis; 2010 Aug; 51(4):448-55. PubMed ID: 20597693
[TBL] [Abstract][Full Text] [Related]
18. Impact of Routine Cryptococcal Antigen Screening and Targeted Preemptive Fluconazole Therapy in Antiretroviral-naive Human Immunodeficiency Virus-infected Adults With CD4 Cell Counts <100/μL: A Systematic Review and Meta-analysis.
Temfack E; Bigna JJ; Luma HN; Spijker R; Meintjes G; Jarvis JN; Dromer F; Harrison T; Cohen JF; Lortholary O
Clin Infect Dis; 2019 Feb; 68(4):688-698. PubMed ID: 30020446
[TBL] [Abstract][Full Text] [Related]
19. Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study.
Longley N; Jarvis JN; Meintjes G; Boulle A; Cross A; Kelly N; Govender NP; Bekker LG; Wood R; Harrison TS
Clin Infect Dis; 2016 Mar; 62(5):581-587. PubMed ID: 26565007
[TBL] [Abstract][Full Text] [Related]
20. Laboratory-Reflex Cryptococcal Antigen Screening Is Associated With a Survival Benefit in Tanzania.
Faini D; Kalinjuma AV; Katende A; Mbwaji G; Mnzava D; Nyuri A; Glass TR; Furrer H; Hatz C; Boulware DR; Letang E
J Acquir Immune Defic Syndr; 2019 Feb; 80(2):205-213. PubMed ID: 30422904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
